BioNTech Plans To Swap Chemotherapy For Gilead's Trodelvy In Its Pumitamig Breast Cancer Trial
Gilead will supply Trodelvy for the ROSETTA Breast-01 study, though the change awaits approval from regulators.
BioNTech said Thursday it has signed a clinical trial collaboration and supply agreement with Gilead Sciences to test its drug candidate pumitamig with Gilead's Trodelvy (sacituzumab govitecan) in a late-stage breast cancer trial. The plan is to replace chemotherapy in the trial with Trodelvy, pending regulatory authority approval, according to the company's release, which was furnished to the SEC on Form 6-K.
What the release says
The trial is ROSETTA Breast-01, a global, double-blinded late-stage study in locally advanced or metastatic triple-negative breast cancer that is PD-L1 low or negative. It currently compares pumitamig plus chemotherapy against chemotherapy, and was started on the strength of positive results from a global mid-stage trial.
BioNTech and its development partner Bristol Myers Squibb plan to adapt the study so that Trodelvy takes chemotherapy's place. The release does not say how the comparison arm would change.
BioNTech will keep sponsoring and leading the trial. Gilead will supply Trodelvy, an antibody-drug conjugate, a drug that delivers a toxic payload to cancer cells.
If the change goes ahead, the company said, it would be the first global late-stage trial of pumitamig combined with an antibody-drug conjugate. The company also said the safety and efficacy of the combination has not been established.
Why the trial is being changed
Peter Schmid, the trial's lead investigator and Director of the Breast Cancer Centre at St. Bartholomew's Hospital, said chemotherapy was the only option for PD-L1 negative advanced disease when the trial began. Drugs like Trodelvy, he said, "are quickly becoming the new global standard of care."
Prof. Özlem Türeci, BioNTech's Co-Founder and Chief Medical Officer, said adapting the trial to the evolving standard of care "gives the trial the best chance to inform clinical practice."
Pumitamig is an investigational drug aimed at two targets, PD-L1 and VEGF-A, and is developed jointly by BioNTech and Bristol Myers Squibb. More than 4,000 patients have been treated with it so far, the company said. It is in seven ongoing global late-stage trials and more than 10 mid-stage combination trials.
The release says the two companies plan further late-stage combination trials in multiple solid tumors.
What to watch
BioNTech will report third-quarter 2026 results on Tuesday, Nov. 3, with a conference call at 8:00 a.m. ET.
Regulatory authority approval of the trial change is the step the release makes the condition for swapping out chemotherapy.
Sources
- Form 6-K — BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer — SEC EDGAR
- BioNTech Advances Phase 3 Clinical Trial of Pumitamig in — globenewswire.com
- BioNTech Advances Phase 3 Clinical Trial of Pumitamig in — globenewswire.com
- BioNTech to Report Third Quarter 2026 Financial Results and — globenewswire.com
- BioNTech to Report Third Quarter 2026 Financial Results and — globenewswire.com